Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 4/20 | 0.64 |
| ▸ | STS | P08842 | 5/20 | 0.55 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 7/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | PGR | P06401 | 3/20 | 0.39 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SNCA | P37840 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257193 | 0.96 | SHBG (0.59) | SHBGSTSHSD17B1ESR1ESR2 | |
| SCHEMBL6266816 | 0.81 | SHBG (0.43) | SHBGSTSHSD17B1ESR1ESR2 | |
| SCHEMBL13725675 | 0.81 | SHBG (0.70) | SHBGSTSHSD17B1ESR1ESR2 | |
| SCHEMBL975788 | 0.81 | SHBG (0.70) | SHBGSTSHSD17B1ESR1ESR2 | |
| SCHEMBL30887214 | 0.81 | SHBG (0.70) | SHBGSTSHSD17B1ESR1ESR2 | |
| SCHEMBL29446097 | 0.81 | SHBG (0.70) | SHBGSTSHSD17B1ESR1ESR2 | |
| SCHEMBL11096655 | 0.81 | SHBG (0.70) | SHBGSTSHSD17B1ESR1ESR2 | |
| SCHEMBL8710195 | 0.80 | STS (0.47) | SHBGSTSHSD17B1ESR1ESR2 | |
| SCHEMBL7165568 | 0.79 | STS (0.65) | SHBGSTSHSD17B1ESR1ESR2 | |
| SCHEMBL21356582 | 0.79 | STS (0.65) | SHBGSTSHSD17B1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221841-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | STERIX LIMITED (GB) | 2009-09-03 | — | — | US | claimed |
| EP-1599493-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | Schering Aktiengesellschaft (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2004074307-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | WO | claimed |
| US-8026229-B2 | Inhibiting tubulin polymerization; treating prostate and breast cancer | STERIX LIMITED (GB) | 2011-09-27 | — | — | US | disclosed |
| EP-1599493-B1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | STERIX LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| EP-1599493-B1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | STERIX LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| EP-1418921-B1 | ANTI-TUMOUR 2-ALKOXYESTRADIOL SULFAMATES | STERIX LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-7067683-B2 | Industrially applicable process for the sulfamoylation of alcohols and phenols | SCHERING AG (DE) | 2006-06-27 | — | — | US | disclosed |
| EP-1456224-B1 | INDUSTRIALLY APPLICABLE PROCESS FOR THE SULFAMOYLATION OF ALCOHOLS AND PHENOLS | SCHERING AG (DE) | 2006-02-08 | — | — | EP | disclosed |
| EP-1599493-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | Schering Aktiengesellschaft (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1456224-A2 | INDUSTRIALLY APPLICABLE PROCESS FOR THE SULFAMOYLATION OF ALCOHOLS AND PHENOLS | Schering Aktiengesellschaft (DE) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004074307-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | WO | disclosed |
| EP-1418921-A1 | ANTI-TUMOUR 2-ALKOXYESTRADIOL SULFAMATES | Schering AG (DE) | 2004-05-19 | — | — | EP | disclosed |
| US-20030171346-A1 | Industrially applicable process for the sulfamoylation of alcohols and phenols | SCHERING AG (DE) | 2003-09-11 | — | — | US | disclosed |
| WO-2003053992-A2 | INDUSTRIALLY APPLICABLE PROCESS FOR THE SULFAMOYLATION OF ALCOHOLS AND PHENOLS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-03 | — | — | WO | disclosed |
| US-6583130-B1 | Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors | SCHERING AG (DE) | 2003-06-24 | — | — | US | disclosed |
| US-6583130-B1 | Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors | SCHERING AG (DE) | 2003-06-24 | — | — | US | disclosed |
| US-6583130-B1 | Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors | SCHERING AG (DE) | 2003-06-24 | — | — | US | disclosed |
| US-20030100544-A1 | Inhibiting tubulin polymerization; treating prostate and breast cancer | SCHERING AG (DE) | 2003-05-29 | — | — | US | disclosed |
| WO-2003015792-A1 | ANTI-TUMOUR 2-ALKOXYESTRADIOL SULFAMATES | SCHERING AG (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171346-A1 | Industrially applicable process for the sulfamoylation of alcohols and phenols | HSD17B11, ADH1C, ADH1A | SHBG 57/4885STS 5/4885HSD17B1 13/4885 |
| US-20030100544-A1 | Inhibiting tubulin polymerization; treating prostate and breast cancer | TUBA1C, TUBB1, NR5A1 | SHBG 60/4885STS 399/4885HSD17B1 27/4885 |
| US-20090221841-A1 | 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-YL SULFAMATE WITH AN ANTI-TUMOUR ACTION | SULT1E1, SULT1A1, SULT2A1 | SHBG 14/4885STS 5/4885HSD17B1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.